MarkWide Research

Sale!

Guillain-Barre Syndrome Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: August, 2022
No of Pages: 168
Delivery Format: PDF+ Excel

$2,950.00

Guillain-Barre Syndrome is a rare immune system disorder. In this medical condition, the patients’ immune system attacks their nervous system. The causative agents of the Guillain-Barre Syndrome are unknown. However, it is illuminated that the disease is often accompanied by infections including respiratory infection and stomach flu. The weakness of legs, difficulty in breathing, low or high blood pressure, difficulty with eye or facial movements is some of the common symptoms of the Guillain-Barre Syndrome.

The increasing prevalence of the Guillain-Barre Syndrome is expected to be one of the major drivers for the market growth during the forecast period. According to a study published by the PLOS One Journal in 2017, Guillain-Barre Syndrome is amongst some of the most common types of serious acute paralytic neuropathy. Moreover, it was estimated that about 100,000 new cases of the disease are reported, annually across the globe.

Guillain-Barre Syndrome Market Report Scope and Segmentation

ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Additionally, growing geriatric population and increasing prevalence of chikungunya boost the market growth. According to the World Health Organization in 2016, about 349 936 suspected and 146,914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported most of the cases were Brazil (265,000 suspected cases), Bolivia, and Colombia (19,000 suspected cases). However, lack of awareness for the disease, absence of any definitive treatment, and low per capita healthcare expenditures in the middle- and low-income countries are estimated to restrain the market growth during the projected period.

Guillain-Barre Syndrome market is expected to grow at an approximate CAGR of 5.4% during the forecast period.

Segmentation

The Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.

Research Methodology

Sources: World Health Organization, PLOS One journal, Mayo Foundation for Medical Education and Research, Annual Reports, Press Release, White Paper, and Company Presentation

Regional Analysis

America dominates the Guillain-Barre Syndrome market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.

Europe stands second in the Guillain-Barre Syndrome market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.

Asia Pacific is projected to be the fastest growing region for the Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.

On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.

Key Players in the Guillain-Barre Syndrome Market

The key players in the Guillain-Barre Syndrome Market are Grifols (Spain), Baxter (U.S.), CSL Behring (U.S.), Akari Therapeutics Plc (U.S.), ANNEXON, INC. (U.S.), Curavac (Europe), Hansa Medical (Sweden), Vitality Biopharma (U.S.), Covidien Limited (Republic of Ireland), Natus Medical Inc. (U.S.), Electrical Geodesics Inc. (U.S.), and others.

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Guillain-Barre Syndrome Market, By Type

6.1 Introduction

6.2 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)

Market Estimates & Forecast, 2020–2027

6.3 Miller Fisher Syndrome (MFS)

Market Estimates & Forecast, 2020–2027

6.3 Acute Motor Axonal Neuropathy (AMAN)

Market Estimates & Forecast, 2020–2027

6.4 Others

Chapter 7. Global Guillain-Barre Syndrome Market, By Diagnosis

7.1 Introduction

7.2 Lumbar Puncture

Market Estimates & Forecast, 2020–2027

7.3 Electromyography

Market Estimates & Forecast, 2020–2027

7.3.1 Intramuscular EMG

7.3.1 Surface EMG

7.4 Nerve Conduction Studies

Market Estimates & Forecast, 2020–2027

7.5 Others

Chapter 8. Global Guillain-Barre Syndrome Market, By Treatment

8.1 Introduction

8.2 Plasmapheresis

Market Estimates & Forecast, 2020–2027

8.3 Medication

Market Estimates & Forecast, 2020–2027

8.3.1 Privigen Intravenous

8.3.2 Gammagard Liquid Injection

8.3.3 Flebogamma DIF Intravenous

8.3.4 Bivigam Intravenous

8.4 Physical Therapy

Market Estimates & Forecast, 2020–2027

8.5 Hydrotherapy

Market Estimates & Forecast, 2020–2027

8.6 Others

Chapter 9. Global Guillain-Barre Syndrome Market, By End-User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2020–2027

9.3 Diagnostic Centers

Market Estimates & Forecast, 2020–2027

9.4 Others

Chapter 10. Global Guillain-Barre Syndrome Market, By Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest Of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic Of Korea

10.4.6 Rest Of Asia Pacific

10.5 Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest Of The Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Grifols

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 Baxter

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 CSL Behring

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Akari Therapeutics Plc

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 ANNEXON, INC.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial Overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Curavac

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Hansa Medical

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Vitality Biopharma

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Covidien Limited

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Natus Medical Inc.

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Electrical Geodesics Inc.

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs Of The Market

13.2 Key Companies To Watch

13.3 Prediction Of Guillain-Barre Syndrome Market

On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.

Grifols (Spain), Baxter (U.S.), CSL Behring (U.S.), Akari Therapeutics Plc (U.S.), ANNEXON, INC. (U.S.), Curavac (Europe), Hansa Medical (Sweden), Vitality Biopharma (U.S.), Covidien Limited (Republic of Ireland), Natus Medical Inc. (U.S.), Electrical Geodesics Inc. (U.S.), and others.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF